|Title||AACR-KCA Joint Conference 2021|
AACR-KCA Joint Conference 2021
PharmAbcine, a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company presented e-poster presentations on the nonclinical data of PMC-403, a vessel normalizing antibody candidate, and PMC-309, a novel VISTA-targeting antibody candidate, at AACR-KCA November 11-12, 2021 (KST).
AACR-KCA is a joint conference with AACR (American Association for Cancer Research) and KCA (Korean Cancer Association), and this year’s 2nd annual conference was on precision medicine in solid tumors.
The e-posters highlighted the vessel normalization effects of PMC-403 in ophthalmology animal models and enhanced anti-tumor effects of PMC-309 when used in combo with the existing drugs.
■ Visit the link below for the event.